Publications

NK100 in Cancer Research

GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity

FT500 IND Clearance

Fate Therapeutics Announces FDA Clearance Of Landmark IND For FT500 IPSC-Derived, Off-The-Shelf NK Cell Cancer Immunotherapy

FT500 iPSC-Derived NK Cell Cancer Immunotherapy (2018 ASH)

iPSC-Derived NK Cells and Anti-PD1 Antibody Synergize to Enhance T-Cell Cytokine and Cytolytic Responses Against Multiple Tumors


2018 AACR Poster

AACR18 FT500 Poster Session

Checkpoint Blockade Resistance

Resistance to Checkpoint Blockade Therapy through Inactivation of Antigen Presentation

59th American Society of Hematology (ASH) Annual Meeting and Exposition

FT516 iPSC-derived hnCD16 NK Cell Cancer Immunotherapy

FT596 iPSC-Derived NK Cell Cancer Immunotherapy (2018 ASH)

Off-the-Shelf Natural Killer Cells with Multi-Functional Engineering Using a Novel Anti-CD19 Chimeric Antigen Receptor Combined with Stabilized CD16 and IL15 Expression to Enhance Directed Anti-Tumor Activity

FT538 iPSC-Derived NK Cell Cancer Immunotherapy (2018 ASH)

CD38 Deficient, CD16 Engineered NK Cells Exhibit Enhanced Antibody Dependent Cellular Cytotoxicity without NK Cell Fratricide to Augment Anti-Myeloma Immunity in Combination with Daratumumab

FT819 iPSC-derived, TCR-less, CAR19 T Cell (2018 ASH)

Pluripotent Cell-Derived Off-the-Shelf TCR-Less CAR-Targeted Cytotoxic T Cell Therapeutic for the Allogeneic Treatment of B Cell Malignancies


Nature. 2017 Mar 2; 543(7643): 113–117.

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

ASH Annual Meeting 2018

ProTmune, a Next-Generation Graft for GvHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: 1-Year Safety and Efficacy Phase 1 Data

Additional Clinical Data from Phase 1 Stage of PROTECT Clinical Trial of ProTmune (EBMT 2018)

Fate Therapeutics Announces Additional Clinical Data from Phase 1 Stage of PROTECT Clinical Trial of ProTmune™

PROTECT Phase 1 Results at Day 100 (ASH 2017)

Fate Therapeutics Announces Day 100 Clinical Results from Phase 1 Stage of PROTECT Trial of ProTmune™ and Initiation of Phase 2 Stage

Stem Cell Reports

Platform for Induction and Maintenance of Transgene-free hiPSCs Resembling Ground State Pluripotent Stem Cells